Table S1. Summary of adverse events.

Adverse event	Number (%) of patients	Number of events
Any adverse event	886 (26.3%)	1,246
Serious adverse events	53 (1.6%)	57
Adverse drug reaction	440 (13.1%)	554
Cardiac disorders	4 (0.1%)	4
Eye disorders	1 (0.03%)	1
Gastrointestinal disorders	61 (1.8%)	63
General disorders and administration site conditions	23 (0.7%)	24
Infections and infestations	54 (1.6%)	54
Investigations (body weight loss, etc.)	106 (3.1%)	109
Metabolism and nutrition disorders	71 (2.1%)	73
Musculoskeletal and connective tissue disorders	2 (0.1%)	2
Nervous system disorders	25 (0.7%)	30
Psychiatric disorders	1 (0.03%)	1
Renal and urinary disorders	127 (3.8%)	132
Reproductive system and breast disorders	40 (1.2%)	42
Skin and subcutaneous tissue disorders	16 (0.5%)	17
Vascular disorders	2 (0.1%)	2

Total n=3,371.

Figure S1. The receiver operating characteristic (ROC) curve for calculating the cutoff value for the relative change expectation of relative HbA1c levels >10% from the baseline.



HbA1c reduction from baseline(%) :

Rate of change = [(Before Forxiga (Baseline)) - (After Forxiga (≥ 12 weeks))]/(Before Forxiga (Baseline))x100

Dependent variable:

Rate of change: HbA1c reduction from baseline more than 10% (Reference= HbA1c reduction less than 10%)

Subjects with all information of HbA1c in prior to and after administration Forxiga are analyzed